LON:VRCI Verici Dx (VRCI) Share Price, News & Analysis GBX 0.22 -0.01 (-2.67%) As of 10:09 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsNews and Trends About Verici Dx Stock (LON:VRCI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Verici Dx alerts:Sign Up Key Stats Today's Range 0.20▼ 0.2550-Day Range 0.20▼ 0.4052-Week Range 0.20▼ 0.99Volume521,588 shsAverage Volume1.71 million shsMarket Capitalization£5.01 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage. The Company also has a mission to accelerate the pace of innovation by research using the fully characterised data from the underlying technology, including through collaboration with medical device, biopharmaceutical and data science partners. The foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant. Read More Receive VRCI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Verici Dx and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VRCI Stock News HeadlinesVerici Dx Secures Shareholder Backing as All AGM Resolutions PassJuly 28, 2026 | tipranks.comVerici Dx to Host Investor Presentation on Results and FundraiseJuly 6, 2026 | tipranks.comThe New Kings of CantillonIn 1720, Richard Cantillon discovered that new money never spreads evenly through an economy. It reaches certain hands first and everyone else pays for it later. Fifty years after the petrodollar reshaped global wealth, a new monetary reset may be underway, this time tied to critical minerals, energy, and AI infrastructure. Stocks like Vertiv, GE Vernova, Arista Networks, and Taseko Mines have already posted major gains since the shift began. Porter Stansberry breaks down the full story, including which companies sit closest to the new money flow.August 26 at 1:00 AM | Porter & Company (Ad)Verici Dx Receives New York State Approval, Establishing Nationwide Access to Tutivia™ Kidney Transplant Rejection TestJune 25, 2026 | uk.finance.yahoo.comVerici Dx gains shareholder backing for major share issue and LSE admissionJune 22, 2026 | tipranks.comVerici Dx Collaborators to Present Data on Predictive Value of Tutivia™ for Acute Kidney Transplant Rejection at ATC 2026June 17, 2026 | finance.yahoo.comVerici Dx calls shareholder meeting to approve new share issuance after fundraisingJune 8, 2026 | tipranks.comVerici Dx Announces Publication Validating Pre-Transplant Gene Signature Test for Predicting Early Acute Rejection in Kidney Transplant RecipientsMay 19, 2026 | finance.yahoo.comSee More Headlines VRCI Stock Analysis - Frequently Asked Questions How have VRCI shares performed this year? Verici Dx's stock was trading at GBX 0.75 at the beginning of the year. Since then, VRCI shares have decreased by 70.8% and is now trading at GBX 0.22. How do I buy shares of Verici Dx? Shares of VRCI stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Verici Dx own? Based on aggregate information from My MarketBeat watchlists, some other companies that Verici Dx investors own include AutoZone (AZO), Intel (INTC), TJX Companies (TJX), Abacus Health Products (ABAHF), Avino Silver & Gold Mines (ASM), Bank of America (BAC) and Cal-Maine Foods (CALM). Industry, Sector and Symbol Stock ExchangeLON SectorHealthcare Industry Life Sciences Tools & Services Sub-IndustryLife Sciences Tools & Services Current SymbolLON:VRCI CIKN/A Webwww.vericidx.com Phone44 207 9338780FaxN/AEmployees19Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (0.90) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£6.56 million Net Margins-193.05% Pretax MarginN/A Return on Equity-138.93% Return on Assets-26.14% Debt Debt-to-Equity Ratio3.03 Current Ratio3.94 Quick Ratio8.49 Sales & Book Value Annual Sales£3.66 million Price / Sales1.37 Cash FlowGBX 0.17 per share Price / Cash Flow1.31 Book ValueGBX 4.43 per share Price / Book0.05Miscellaneous Outstanding Shares2,287,311,000Free FloatN/AMarket Cap£5.01 million OptionableNot Optionable Beta1.26 The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (LON:VRCI) was last updated on 8/26/2026 by MarketBeat.com Staff. From Our PartnersSomeone just dumped the biggest gold fund.Investors pulled 2.9 billion dollars from the world's largest gold fund in a single day this March, pushing to...Behind the Markets | SponsoredA $382 trillion migration and the position no one is talking aboutTrump just signed a law requiring America's entire $382 trillion financial system to migrate to a new money ne...Awesomely | SponsoredBezos… DOOMEDA single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...Paradigm Press | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredYour withdrawal order could cost you in taxesIf you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...SmartAsset | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredJeff Brown and Marc Chaikin's latest AI prediction explainedJeff Brown and Marc Chaikin - the duo who identified Nvidia a decade ago - are forecasting that Elon Musk's AI...Brownstone Research | SponsoredBuy this stock todayMost tech companies skip dividends entirely. This one doesn't, paying shareholders like clockwork while flying...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verici Dx plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Verici Dx With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
